Cevidoplenib
Phase 2SYK inhibitor that completed global phase 2 studies, including in immune thrombocytopenia, and was licensed to a US company for development and commercialisation.
FROM PUBLIC EVENTS · 2026-11-15
Early clinical · first deals Licensed its phase 2 autoimmune candidate to a US company and is developing follow-on candidates.
Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing
A small-molecule drug developer that licensed its autoimmune candidate cevidoplenib to a US company in 2026.
SYK inhibitor that completed global phase 2 studies, including in immune thrombocytopenia, and was licensed to a US company for development and commercialisation.
Licensed global exclusive rights to cevidoplenib to a US company in a deal worth up to about KRW 1 trillion.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.